title: [Retrospective analysis of 54 patients with high risk aggressive T-cell non-Hodgkin lymphomas].
abstract: OBJECTIVE
  To analyse the clinical characteristics, treatments and prognosis of patients with T-cell non-Hodgkins lymphoma (NHL) in intermediate-high and high risk.
  
  
  METHODS
  Fifty-four patients with T-cell NHL classified intermediate-high and high risk were retrospectively analyzed.
  
  
  RESULTS
  According to WHO classification criteria, there were 12 cases of T-lymphoblastic lymphoma (TLBL), 31 peripheral T-cell lymphoma unspecified (PTCL-U), and 11 hepatosplenic T-cell lymphoma (HSTCL). The IPI were 12 cases of intermediate-high risk and 42 high risk. Of them, 49 cases were bone marrow affected and 7 CNS affected. The response rate (RR) for the whole group was 86.5%, complete remission (CR) rate 67.3%, and 3-year survival rate 16.0%. The 3-year survival rates for haematopoietic stem cell transplantation and chemotherapy groups were 44.4% and 8.3%, respectively. Multi-factor analysis showed that choice of therapy modality, and achievement of remission were significant factors for overall survival.
  
  
  CONCLUSIONS
  T-NHL is a group of heterogeneous malignancies. The response rate of intermediate-high and high risk T- NHL, especially PTCL-U and LTBL, is not low, but its long-term outcome is poor. New treatment modality needs to be explored for these patients, and autologous HSCT is perhaps a good choice.
authors: State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC, Tianjin 30020, China.
authors: Xiao-Li
authors: XL
authors: Yuan
authors: Qiao-Chuan
authors: QC
authors: Li
authors: De-Hui
authors: DH
authors: Zou
authors: Yao-Zhong
authors: YZ
authors: Zhao
authors: Ya-Fei
authors: YF
authors: Wang
authors: Ying
authors: Y
authors: Wang
authors: Jing-Wei
authors: JW
authors: Zhang
authors: Lu-Gui
authors: LG
authors: Qiu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D016896:Treatment Outcome